Mitochondrial Complex I Is an Essential Player in LPS-Induced Preconditioning in Differentiated PC12 Cells

Nasim Manouchehri, Fariba Khodagholi, Leila Dargahi and Abolhassan Ahmadiani

Abstract

Preconditioning (PC) as a protective strategy against noxious insults can decline cell death and apoptosis. It has been approved that mitochondria play a key role in PC mechanism. The critical role of complex I (CI) in oxidative phosphorylation machinery and intracellular ROS production, particularly in the brain, accentuates its possible role in PC-induced neuroprotection. Here, differentiated PC12 cells were preconditioned with ultra-low dose LPS (ULD, 3 μg/mL) prior to exposure to high concentration of LPS (HD, 750 μg/mL). Our results showed that HD LPS treatment reduces cell viability and CI activity, and intensifies expression of cleaved caspase 3 compared to the control group. Intriguingly, PC induction resulted in enhancement of cell viability and CI activity and reduction of caspase3 cleavage compared to HD LPS group. In order to explore the role of CI in PC, we combined the ULD LPS with rotenone, a CI inhibitor. Following rotenone administration, cell viability significantly reduced while caspase3 cleavage increased compared to PC induction group. Taken together, cell survival and reduction of apoptosis followed by PC can be at least partially attributed to the preservation of mitochondrial CI function.

Keywords: Mitochondrial complex I; Preconditioning; Neuroinflammation; Neuroprotection; Mitochondria.

Introduction

Lipopolysaccharides (LPS), known as endotoxins and lipoglycans, are the main part of the gram-negative bacteria outer membrane. LPS binds to the Toll-like receptors (TLRs) expressed by various types of cells in nervous system including neurons and glial cells and promotes the release of chemokines and pro-inflammatory factors such as tumor necrosis factor alpha (TNFα) and interleukin-1β (IL-1β) which ultimately induces neuroinflammation (1-3).

Preconditioning (PC) is a phenomenon in which different organs of the body like brain and heart will be protected against subsequent injurious damage by accommodating to low doses of harmful injuries. PC paradigms consist of low doses of endotoxins such as LPS, hypoxia, hyperthermia, hyperthermia, anesthetics, 3-nitropropionic acid, etc.

The PC mitigates neuroinflammation which results in neuroprotection. For example, LPS preconditioning plays a key role in reducing inflammation-induced apoptosis in spinal cord injury that consequently leads to neuroprotection (4). Although various mechanisms have been
proposed for PC, the precise mechanism is unknown. Mitochondria as gate of cell death and survival, can play main role in PC mechanism (5). Leading role of mitochondria in the PC mechanism has been mostly considered in heart, brain, and neurodegenerative disorders (6, 7). Mitochondria produce adenosine tri-Phosphate (ATP) through electron transport chain (ETC) which are of particular importance to neurons (8). Mitochondrial impairment and oxidative phosphorylation (OXPHOS) disruption are unequivocal causes of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Huntington disease (9-17). Inflammation impairs mitochondrial function that leads to mitochondrial DNA (mtDNA) deficiency, mitochondrial respiratory chain dysfunction and eventually cell death (18-20). Mitochondrial respiratory chain is central source of ROS generation and its dysfunction results in increment of ROS production which consequently causes oxidative stress, a robust stimulus for promoting inflammation (21, 22). Therefore, mitochondrial dysfunction and excessive ROS production can lead to mitophagy and mitochondrial degradation (23). It has been recently shown that LPS can stimulate autophagy and mitophagy through oxidative stress induction. Whereas, LPS-induced tolerance could increase protein level of mitochondrial CI and mitochondrial complex IV (CIV) in THP-1 cells (24). The ETC, as a collection of proteins embedded in the inner mitochondrial membrane, is organized into five grand complexes named I to V. Passage of electrons from one complex of the transport chain to another lead to energy production. This process named proton gradient which is essential for ATP generation (25). The largest complex of ETC, complex I (NADH-ubiquinone oxidoreductase), oxidizes nicotinamide adenine dinucleotide (NADH) to NAD⁺ and produces 2 electron that subsequently transfer to complex III (CIII). Moreover, the CI pumps proton from matrix to intermembrane space for generation of proton gradient (26). The CI is also the main origin of intracellular ROS, specifically in the brain’s mitochondria (27). Thus, it is not surprising that the CI inhibition can result in energy failure and increase ROS levels dramatically (8). Therefore, it has become evident that disturbance of mitochondrial CI function can cause the onset or progression of neurodegenerative disorders (13, 28-30). Given that the destructive effects of neuroinflammation on mitochondria may be attenuated by various mechanisms including generation of anti-inflammatory factors, preservation of mitochondrial integrity through mitophagy and production of new organelles by mitochondrial biogenesis (31, 32). However, the exact mechanism of these compensatory responses is unknown. Therefore, regarding the role of CI in OXPHOS machinery; here, we are going to reveal the role of mitochondrial CI in the mechanism underlying LPS-PC neuroprotection.

**Experimental**

**Cell culture**

This study received written approval from the Neuroscience Research Center Ethics Board (code IR.SBMU.PHNS.1394.49). PC12 cells (pheochromocytoma cells derived from the adrenal gland of Rattus norvegicus), purchased from Pasteur Institute (Tehran, Iran), were grown in T-75 cm² culture flasks in complete (DMEM) medium, containing 5% fetal bovine serum (FBS), 10% horse serum, and 1% antibiotic mixture comprising penicillin-streptomycin, at 37 °C with 5% CO₂ and treated with nerve growth factor (NGF) (50 ng/mL) for 6 days (33). The cells were used when the density of the cell cultures reached 70–80%.

**Detection of the toxic dose of LPS**

Differentiated PC12 cells (1 × 10⁴/well), in 96-well plates, were treated with different LPS concentrations including 0.25, 0.5, 0.75, and 1 mg/mL, to find out the appropriate toxic dose of LPS mentioned as high dose (HD) later in this study. The cell survival rate was examined after 24 h, using MTT assay.

**Detection of appropriate time course of PC**

In order to find the best time for LPS-induced tolerance model, the differentiated PC12 cells were seeded at a density of 1 × 10⁴ cells/well in 96-well plates, and treated with ultra-low dose (ULD) of LPS (3 µg/mL). After 4, 6, 8, 12, and
The role of mitochondrial complex I in the mechanism underlying LPS-PC neuroprotection

Briefly, PC12 cells were seeded at a density of $1 \times 10^6$ cells/mL in T-75 cm$^2$ tissue culture flask and divided into six experimental groups: 1) Cells that received media as control group, 2) cells that received HD LPS (750 µg/mL) named as HD group, 3) cells treated by ULD LPS (3 µg/mL) for PC induction and after 12 h, exposed to HD LPS named as PC group, 4) cells that received rotenone (5 µM) as mitochondrial complex I inhibitor and named as R group (34), 5) cells that co-administrated with rotenone and HD LPS named as R+HD group, and 6) cells that were incubated with rotenone before PC induction and indicated as R+PC.

The cells in all experimental groups, were harvested after 24 h and washed three times with phosphate buffered saline (PBS) for later tests.

Measurement of cell viability

Cell survival was assessed by the conventional MTT (3-[4, 5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) reduction assay. Viable cells that contain intact mitochondria reduce MTT to dark purple formazan crystals. Then, formazan crystals were solubilized in Dimethyl sulfoxide (DMSO) and the absorbance was measured at 570 nm (35). Results are presented as the percentages of reduced MTT, assuming the absorbance of control cells as 100%.

Preparation of total protein extracts

To obtain total cell extracts, the treated cells were harvested, washed with ice-cold Phosphate buffered saline (PBS), and resuspended in lysis buffer. For western blot, the collected cells were lysed in RIPA buffer containing protease inhibitors and for complex activity assay; the proteins were extracted using the detergent provided by the assay kit manufacturer. After 30 min incubation on ice, cellular debris were removed by centrifugation at 13000 rpm at 4 °C for 25 min. Protein content was determined according to the Bradford’s method using bovine serum albumin (BSA) as a reference standard (36).

Western blot analysis

Sixty microgram of total protein per sample were loaded on SDS-PAGE gel and transferred to polyvinylidene fluoride membrane (PVDF) (Millipore, Billerica, MA). Subsequently, the membranes were blocked by non-fat dry milk-TBST solution (2%) and probed with primary antibodies (anti-β-actin as the housekeeping protein (1:1000) and Anti-caspase 3 (1:1000)) overnight at 4 °C For immunodetection. After three times washing, the blots were incubated for 90 min at room temperature with horseradish peroxidase (HRP)-conjugated secondary antibody (1:3000). Immunoreactive polypeptides were detected by chemiluminescence using ECL kit reagents (Amersham Bioscience, Piscataway, NJ). Finally, the signals generated were quantified using the ImageJ software.

Determination of Mitochondrial complex I activity

The cellular mitochondrial complex I activity was evaluated spectrophotometrically using Abcam’s microplate assay kit, according to the manufacturer’s instructions, which takes place by the oxidation of reduced NADH to NAD$^+$ and the coincident reduction of a dye that results in enhanced absorbance at OD = 450 nm. Equal amounts of each sample were loaded onto the plate. Complex activity is expressed as the change in absorbance per minute per microgram protein loaded.

Materials

LPS from Escherichia coli 055:B5 (L2880) and rotenone (R8875) were purchased from Sigma Aldrich (St. Louis, MO, USA). Antibodies used against caspase-3 (9665) and β-actin (4970) were purchased from Cell Signaling Technology. The anti-rabbit horseradish peroxidase (HRP) linked secondary antibody (1:3000) (7074) was purchased from Cell Signaling Technology (Beverly, MA, USA). Mitochondrial complex I (ab109721) assay kit was purchased from Abcam (Cambridge, MA, UK).

Statistical Analysis

All data were analyzed using the one-way ANOVA followed by Tukey post-hoc test using GraphPad Prism software. In all analyses,
P < 0.05 was considered statistically significant. All data were presented as mean ± SEM.

Results

The concentration of 0.75 mg/mL was selected as HD LPS
LPS reduced cell viability at 0.5, 0.75 and 1 mg/mL concentrations (P < 0.05, P < 0.001 and P < 0.001, respectively), while the lower concentration (0.25 mg/mL) did not change cell viability (Figure 1). The concentration of 0.75 mg/mL was selected for later experiments and considered as HD LPS.

The time course of 12 h was selected for PC induction
PC12 cells treated with ULD LPS were exposed to HD LPS as the toxic dose after 4, 6, 8, 12, and 24 h. Our data showed that pretreatment by ULD LPS 12 h before the HD exposure leads to preservation of cell viability compared to HD LPS (P < 0.05). This is while, as shown in Figure 2, intervals of 4, 6 and 8 h between ULD and HD LPS didn’t show any significant difference in cell survival in comparison to HD LPS treatment alone. On the other side, because there was statistically no significant discrepancy between PC induction and ctrl group in pretreatment by ULD LPS 24 h before the HD exposure, therefore 24 h interval between ULD and HD could lead to conservation of cell survival.

Complex I activity was preserved by PC induction
The activity of mitochondrial CI activity was expressed as the change in absorbance per minute per microgram protein loaded. As shown in Figure 3, Complex I activity reduced in HD treated cells (P < 0.01). But, PC induction preserved complex I activity compared to HD group (P < 0.001). Rotenone, as CI inhibitor, decreased CI activity (P < 0.05).

Inhibition of mitochondrial complex I, abolished the protective effects of PC on cell survival
As shown in Figure 4, suppression of mitochondrial CI activity by rotenone and co-treatment of cells with both rotenone and HD LPS significantly reduced cell viability (P < 0.001 and P < 0.001, respectively). Interestingly, co-administration of rotenone with PC induction decreased cell viability in neural like cells in comparison with PC group (P < 0.01).
The role of mitochondrial complex I in the mechanism underlying LPS-PC neuroprotection

The protective effect of PC against caspase 3 cleavage was attenuated by the inhibition of mitochondrial complex I

The protein levels of cleaved caspase-3 were measured as a pro-apoptotic factor. Consistent with cell survival data, the western blot data showed that HD LPS increased cleaved caspase3 expression ($P < 0.001$). While rotenone treatment alone did not enhance caspase3 cleavage, co-treatment of rotenone with HD increased the cleaved caspase3 compared to control group ($P < 0.01$). Induction of PC significantly decreased expression of cleaved caspase3 compared to the HD ($P < 0.001$). Also, it was observed that co-administration of rotenone with PC induction enhanced expression of cleaved caspase3.

![Figure 2. Effect of PC and time of incubation on cell viability in neural like cells. Cells (1 x 10⁴/well) were treated with HD LPS and ultra-low dose (ULD) LPS for PC induction for 4, 6, 8, 12, and 24 h, and then, cell viability was measured using MTT test. Cell viability reduced following HD LPS. PC increased cell viability following 12 h interval between HD and ULD, while other intervals did not change cell viability. Data are shown as mean ± SEM. Treatments were repeated 3 times and there were 4 wells in each repeat. *$P < 0.05$ vs. Ctrl. Ctrl: control; HD: high dose lipopolysaccharides (LPS); PC: preconditioning.](image)

![Figure 3. High dose LPS reduced the activity of complex I. HD LPS reduced complex I activity while PC preserved this activity. Data are shown as mean ± SEM. Treatments were repeated 3 times. *$P < 0.05$, **$P < 0.01$ vs. Ctrl, ***$P < 0.001$ vs. HD. Ctrl: control; HD: high dose lipopolysaccharides (LPS); PC: preconditioning; R: Rotenone.](image)
compared to the PC induction (Figure 5).

**Discussion**

Regarding the role of mitochondria in pathogenesis of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and neuroinflammatory diseases like multiple sclerosis (MS) and indispensable protective role of PC in neural damage, in the

![Figure 4](image4.png)

**Figure 4.** Effect of inhibition of complex I and PC on neural like cells measured using MTT test. Inhibition of complex I attenuated the protection effect of PC on cell viability. Data are shown as mean ± SEM. Treatments were repeated 3 times and there were 4 wells in each repeat. ***P < 0.001 vs. Ctrl, **P < 0.01 vs. HD, ***P < 0.001 vs. PC. Ctrl: Control; HD: high dose lipopolysaccharide (LPS); PC: preconditioning; R: Rotenone.

![Figure 5](image5.png)

**Figure 5.** The role of complex I in protective effect of PC against caspase 3 cleavage induced by high dose LPS. Inhibition of complex I by rotenone increased caspase 3 cleavage. PC prevented the activation of apoptotic pathways in response to high dose LPS. Data are shown as mean ± SEM. Treatments were repeated 3 times. **)P < 0.01; ***)P < 0.001 vs. Ctrl, ***)P < 0.001 vs. HD, ***)P < 0.001 vs. PC. Ctrl: control; HD: high dose lipopolysaccharides (LPS); PC: preconditioning; R: Rotenone.
The role of mitochondrial complex I in the mechanism underlying LPS-PC neuroprotection

In the present study, the main question is whether mitochondrial CI, which plays a crucial role in ATP generation, has any possible role in the PC mechanism. To get insight into the link between CI function and PC mechanism, we examined cell viability, caspase3 cleavage, and the activity of mitochondrial CI. The main findings from this in vitro study were the following: i) 750 µg/mL concentration is the toxic dose of LPS, ii) the most appropriate time for the PC induction is 12 h interval between ULD LPS and HD LPS, iii) Reduction of caspase3 cleavage and increment of cell survival occur following LPS-induced PC, iv) The activity of CI was preserved by LPS-induced PC, and v) Blockage of the CI activity by rotenone suppressed the protective effects of the PC.

Our results showed that 750 µg/mL concentration is the toxic dose of LPS and the most appropriate time for PC induction is 12 h interval between ULD LPS (for inducing protection) and HD LPS (for noxious insult). In fact, 12 h preconditioning interval increased cell survival from 48% to 81%. On the other hand, since there is no statistically significant difference between PC induction and control group in pretreatment by ULD LPS 24 h before the HD exposure, 24 h interval between ULD and HD can also result in preservation of cell survival. Given the higher percentage of cell survival in 12 h interval, it seems that the PC induces the most effective protection in this time. Consequently, 12 h interval between PC induction and HD LPS exposure was selected as the most appropriate time for PC induction.

Preconditioning with H2O2 for 90 min in PC12 cells, protect the cells against 24 h later exposure to the higher concentrations of H2O2 (37, 38). Meloni and colleagues used erythropoietin (EPO) for PC induction at 8, 12, and 24 h before in-vitro model of ischemia and indicated that EPO preconditioning in neurons and PC12 cells protects them against harmful consequences of ischemia. They also reported that cell viability enhances from 26% to 61% in 8 h PC interval while increase of cell survival up to 89% has been observed in 12- and 24 h PC intervals (39). It has been also demonstrated that 24 h interval between low dose LPS PC and surgery ameliorates the cognitive damage and prohibits neuroinflammation in hippocampus following surgery (40).

LPS has been used frequently to induce preconditioning in several studies. For example, it has been shown that pre-treatment with a single intraperitoneal injection of LPS, 7 days prior to traumatic brain injury, causes a significant neuroprotection in the brain of animals against axonal injury (41). In the other study, preconditioning with LPS 72 h before middle cerebral artery occlusion and 4 days before hemorrhagic shock have proved promising results (42-44). Hence, the neuroprotective effects of LPS or any other preconditioning-inducing agents mainly depend on the time of administration. In general, the best time interval for the applying preconditioning depends on i) the type of paradigms such as H2O2, EPO and LPS, ii) the pathological context, and iii) the study platform, in-vivo/in-vitro.

Given that the MTT test relies on the tetrazolium dye reduction by the mitochondrial dehydrogenases, thus, caspase 3 cleavage as a mitochondrial dependent cell death factor was also investigated. Our findings showed that although HD LPS reduced viable cells and increased caspase 3 cleavage, PC preserved cell survival and significantly attenuated cleaved caspase 3 expression. In agreement with these findings, it has been reported that hyperbaric oxygen PC suppresses pro-apoptotic factors such as caspase3, 7, 8, and 12 following spinal cord injury (45). It has been also indicated that oxygen and glucose deprivation PC significantly attenuate apoptotic cell death in PC12 cells in a cellular model of ischemia (46).

In the next step of study, our data also showed that HD LPS reduced CI activity. Consistent with our results, Callahan and Supinski have reported that the down-regulation of mitochondrial CI, II, and IV occur at the transcription and translation levels within 24 h after exposure to toxic doses of LPS in sepsis model of rats (47). Therefore, other evidence suggests that dysfunction of mitochondrial complexes occurs following neuroinflammation in striatum, substantia nigra, and midbrain in animal models of Parkinson's disease (48-50). Indeed, augmented levels of inflammatory mediators can influence mitochondrial function.
(51, 52). For example, TNFα and IL-1β reduce mitochondrial membrane potential (MMP), ATP generation, and mitochondrial CI activity (53, 54). Zhang and colleagues indicated that LPS PC may notably reduce cognitive damage and surgery-induced neuroinflammation in aging mice (40). It has been also shown that LPS PC can protect dopaminergic neurons against neuroinflammation in rat midbrain (55). Our findings demonstrated that the activity of CI was preserved by LPS-induced PC; this observation is supported by other studies emphasizing the protective effects of PC on mitochondrial structure and function (4, 40, 41, 56 and 57). In a recent study it has been shown that isoflurane PC increases the expression of anti-apoptotic factors including Bcl-XL and Bcl-2, decreases apoptosis, preserves mitochondrial complexes activity and restricts ROS production in neurons (58). It has been demonstrated that complexes I-IV activity preserves following of ischemic PC (IPC) induction (5, 59 and 60). Dave and colleagues showed that there is no significant difference in activity of hippocampal mitochondrial complexes I to IV and oxygen consumption rates between ischemic PC and sham groups (61). In another study, it has been shown that LPS-PC result in mitochondrial biogenesis through the increase of ATP generation, overexpression of mitochondrial protein levels, and enhancement of respiration capacity in-vitro model of ischemia (62).

In the present study, to signify the role of mitochondrial CI in PC-induced protection, we used rotenone as a specific CI inhibitor and the results showed that LPS-induced PC increases cell survival, reduces caspase3 cleavage and stimulates CI activity compared to the cells that received co-administration of rotenone and PC. Rotenone as a robust inhibitor of CI disturbs electron transfer in the ETC, decreases ATP production and enhances ROS generation that ultimately result in oxidative stress and apoptotic cell death (63). Heinz et al. reported that rotenone declines CI activity in isolated liver mitochondria in rats (64). No significant difference between rotenone group and co-treatment of rotenone and PC induction suggests that inhibition of CI can result in reduction of cell viability and prevention of PC-induced neuroprotection.

In the present study our data demonstrated that LPS PC protects neural like cells against inflammatory agents and preserves CI activity. Moreover, blockage of CI activity by rotenone suppressed the protective effects of PC which highlights the major role of mitochondria, specifically CI activity, in the mechanism of LPS-induced PC. Decline of cleaved caspase3 protein levels and increment of cell survival following LPS-induced PC signifies the PC as a protective approach which can be assumed as a novel therapeutic target for prevention and/or treatment of neurodegenerative disorders.

Conclusion

The protective effects of low concentrations of PC compared to the toxic effects of higher concentrations of LPS can be attributed to the preservation of mitochondrial function, particularly the CI activity.

Acknowledgement

This article has been extracted from the thesis written by Mrs. Nasim Manouchehri in Neuroscience Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences (Registration No: 614).

References

(1) Beutler B. Tlr4: central component of the sole mammalian LPS sensor. *Curr. Opin. Immunol.* (2000) 12: 20-6.
(2) Lafon M, Megret F, Lafage M and Prehaud C. The innate immune facet of brain. *J. Mol. Neurosci.* (2006) 29: 185-94.
(3) Barajon I, Serrao G, Aramaboldi F, Opizzi E, Ripamonti G, Balsari A and Rumio C. Toll-like receptors 3, 4, and 7 are expressed in the enteric nervous system and dorsal root ganglia. *J. Histochem. Cytochem.* (2009) 57: 1013-23.
(4) Li WC, Jiang R, Jiang DM, Zhu FC, Su B, Qiao B and Qi XT. Lipopolysaccharide preconditioning attenuates apoptotic processes and improves neuropathologic changes after spinal cord injury in rats. *Int. J. Neurosci.* (2014) 124: 585-92.
(5) Dirnagl U and Meisel A. Endogenous neuroprotection: mitochondria as gateways to cerebral preconditioning? *Neuropharmacology* (2008) 55: 334-44.
(6) Vargas T, Ugalde C, Spuch C, Antequera D, Moran MJ, Martin MA, Ferrer I, Bermejo-Pareja F and Carro...
The role of mitochondrial complex I in the mechanism underlying LPS-PC neuroprotection

E. Abeta accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. Neurobiol. Aging. (2010) 31: 1569-81.

(7) Correia SC, Santos RX, Perry G, Zhu X, Moreira PL and Smith MA. Mitochondria: the missing link between preconditioning and neuroprotection. J. Alzheimers Dis. (2010) 20: S475-585.

(8) Weise J, Engelhorn T, Dörfler A, Aker S, Bähr M and Hufnagel A. Expression time course and spatial distribution of activated caspase-3 after experimental status epilepticus: contribution of delayed neuronal cell death to seizure-induced neuronal injury. Neurobiol. Dis. (2005) 18: 582-90.

(9) Moreira PL, Santos MS, Moreno A, Rego AC and Oliveira C. Effect of amyloid β-peptide on permeability transition pore: A comparative study. J. Neurosci. Res. (2002) 69: 257-67.

(10) Lunnun K, Keohane A, Pidsley R, Newhouse S, Riddoch-Contreras J, Thubron EB, Devall M, Soininen H, Kłoszewska I and Meccoci P. Mitochondrial genes are altered in brain early in Alzheimer’s disease. Neurobiol. Aging. (2017) 53: 36-47.

(11) Xie H, Guan J, Borrelli LA, Xu J, Serrano-Pozo A and Bacskai BJ. Mitochondrial alterations near amyloid plaques in an Alzheimer’s disease mouse model. J. Neurosci. (2013) 33: 17042-51.

(12) Song DD, Shults CW, Sisk A, Rockenstein E and Masliah E. Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP1. Exp. Neurol. (2004) 186: 158-72.

(13) Amo T, Saiki S, Sawayaama T, Sato S and Hattori N. Detailed analysis of mitochondrial respiratory chain defects caused by loss of PINK1. Neurosci. Lett. (2014) 580: 37-40.

(14) Mullin S and Schapira A. α-Synuclein and mitochondrial dysfunction in Parkinson’s disease. Mol. Neurobiol. (2013) 47: 587-97.

(15) Carmo C, Naia L, Lopes C and Rego AC. Mitochondrial dysfunction in Huntington’s disease. Adv. Exp. Med. Biol. (2018) 1049: 59-83.

(16) Damiano M, Galvan L, Déglon N and Brouillet E. Mitochondria in Huntington’s disease. BBA-Mol Basis Dis. (2010) 1802: 52-61.

(17) Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N and Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. CNS Neurosci. Ther. (2017) 23: 5-22.

(18) Brealey D and Singer M. Mitochondrial dysfunction in sepsis. Curr. Infect. Dis. Rep. (2003) 5: 365-71.

(19) Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit. Care Med. (2007) 35: S441-S8.

(20) Noh H, Jeon J and Seo H. Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain. Neurochem. Int. (2014) 69: 35-40.

(21) Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br. J. Anaesth. (2011) 107: 57-64.

(22) Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K and Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature (2010) 464: 104.

(23) Chang AL, Ulrich A, Suliman HB and Piantadosi CA. Redox regulation of mitophagy in the lung during murine Staphylococcus aureus sepsis. Free Radic. Biol. Med. (2015) 78: 179-89.

(24) Widdrington JD, Gomez-Duran A, Pyle A, Ruchaud-Sparagano MH, Scott J, Baudouin SV, Rostron AJ, Lovat PE, Chinnery PF and Simpson AJ. Exposure of monocyctic cells to lipopolysaccharide induces coordinated endotoxin tolerance, mitochondrial biogenesis, mitophagy, and antioxidant defenses. Front. Immunol. (2018) 9: 2217.

(25) Dudkina NV, Sunderhaus S, Boekema EJ and Braun HP. The higher level of organization of the oxidative phosphorylation system: mitochondrial supercomplexes. J. Bioenerg. Biomembr. (2008) 40: 419.

(26) Zickermann V, Kerscher S, Zwicker K, Tocilescu MA, Radermacher M and Brandt U. Architecture of complex I and its implications for electron transfer and proton pumping. Biochim. Biophys. Acta Bioenerg. (2009) 1787: 574-83.

(27) Folbergrová J, Ješina P, Drahota Z, Lisy V, Haugvicová R, Vojtíšková A and Houšťek J. Mitochondrial complex I inhibition in cerebral cortex of immature rats following homocysteic acid-induced seizures. Exp. Neurol. (2007) 204: 597-609.

(28) Panov A, Dikalov S, Shalbueva N, Taylor G, Sherer T and Greenamyre JT. Rotenone model of Parkinson’s disease: Multiple brain mitochondria dysfunctions after short-term systemic rotenone intoxication. World J. Biol. Chem. (2005) 280: 42026-35.

(29) Zhou L, Wang W, Hoppel C, Liu J and Zhu X. Parkinson’s disease-associated pathogenic VP35 mutation causes complex I deficits. BBA-Mol Basis Dis. (2017) 1863: 2791-5.

(30) Orth M and Schapira A. Mitochondria and degenerative disorders. Am. J. Med. Genet. A (2001) 106: 27-36.

(31) López-Armada MJ, Riveiro-Navarre RR, Viamonde-Garcia C and Vallecárcel-Ares MN. Mitochondrial dysfunction and the inflammatory response. Mitochondrion (2013) 13: 106-18.

(32) Piantadosi CA and Suliman HB. Redox regulation of mitochondrial biogenesis. Free Radic. Biol. Med. (2012) 53: 2043-53.

(33) Shaerzadeh F, Ahmadiani A, Esmaeili MA, Ansari N, Asadi S, Tusi SK, Sonboli A, Gha herezmazan M and Khodagholi F. Antioxidant and antiglycatng activities of Salvia sahendica and its protective effect against oxidative stress in neuron-like PC12 cells. J. Nat. Med. (2011) 65: 455.

(34) Uyemura SA, Luo S, Vieira M, Moreno SN and Docampo R. Oxidative phosphorylation and rotenone-insensitive malate-and NADH-quinone
oxidoreductases in Plasmodium yoelii yoelii mitochondria in situ. *J. Biol. Chem.* (2004) 279: 385-93.

(35) Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods* (1983) 65: 55-63.

(36) Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* (1976) 72: 248-54.

(37) Zhu L, Zuo W, Yang H, Zhang H, Luo H, Ye D, Lin X, Mao J, Feng J and Chen L. Involvement of volume-activated chloride channels in H2O2 preconditioning against oxidant-induced injury through modulating cell volume regulation mechanisms and membrane permeability in PC12 cells. *Mol. Neurobiol.* (2013) 48: 205-16.

(38) Mo L, Yang C, Gu M, Zheng D, Lin L, Wang X, Lan A, Hu F and Feng J. PI3K/Akt signaling pathway-induced heme oxygenase-1 upregulation mediates the adaptive cytoprotection of hydrogen peroxide preconditioning against oxidative injury in PC12 cells. *Int. J. Mol. Med.* (2012) 30: 314-20.

(39) Meloni BP, Tillbrook PA, Boulos S, Arthur PG and Knuckey NW. Erythropoietin preconditioning in neuronal cultures: signaling, protection from in-vitro ischemia, and proteomic analysis. *J. Neurosci. Res.* (2006) 83: 584-93.

(40) Zhang Z, Ji M, Liao Y, Yang J and Gao J. Endotoxin tolerance induced by lipopolysaccharide preconditioning protects against surgery-induced cognitive impairment in aging mice. *Mol. Med. Rep.* (2018) 17: 3845-52.

(41) Turner RC, Naser ZJ, Lucke-Wold BP, Logsdon AF, Vangilder RL, Matsumoto RR, Huber JD and Rosen CL. Single low-dose lipopolysaccharide preconditioning: neuroprotective against axonal injury and modulates glial cells. *Neuroimmunol. Neuroinflamm.* (2017) 4: 6.

(42) Vartanian KB, Stevens SL, Marsh BJ, Williams-Karnesky R, Lessov NS and Stenzel-Poore MP. LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. *J. Neuroinflammation* (2011) 8: 140.

(43) Wang Z, Zhou Y, Yu Y, He K and Cheng LM. Lipopolysaccharide preconditioning increased the level of regulatory B cells in the spleen after acute ischemia/reperfusion in mice. *Brain Res.* (2018) 1701: 46-57.

(44) Amini E, Golpich M, Farjam AS, Kamalidehghan B, Mohamed Z, Ibrahim NM, Ahmadiani A and Raymond AA. Brain lipopolysaccharide preconditioning-induced gene reprogramming mediates a tolerance state in electroconvulsive shock model of epilepsy. *Front. Pharmacol.* (2018) 9: 416.

(45) Pan J, Cai R, Chen Y, Li Y, Lin W, Wu J and Wang X. Analysis the effect of hyperbaric oxygen preconditioning on neuronal apoptosis, Ca2+ concentration and caspases expression after spinal cord injury in rats. *Eur. Rev. Med. Pharmacol. Sci.* (2018) 22: 3467-73.

(46) Hillion JA, Takahashi K, Maric D, Ruetzler C, Barker JL and Hallenbeck JM. Development of an ischemic tolerance model in a PC12 cell line. *J. Cereb. Blood Flow Metab.* (2005) 25: 154-62.

(47) Callahan LA and Supinski GS. Downregulation of diaphragm electron transport chain and glycolytic enzyme gene expression in sepsis. *J. Appl. Physiol.* (2005) 99: 1120-6.

(48) Voloboueva LA and Giffard RG. Inflammation, mitochondria, and the inhibition of adult neurogenesis. *J. Neurosci. Res.* (2011) 89: 1989-96.

(49) Thakur Pand Nehru B. Inhibition of neuroinflammation and mitochondrial dysfunctions by carbonoxolone in the rotenone model of Parkinson’s disease. *Mol. Neurobiol.* (2015) 51: 209-19.

(50) Choi DY, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, Shin EJ, Kim HC, Gash DM and Bing G. Striatal neuroinflammation promotes Parkinsonism in rats. *Plos One* (2009) 4: e5482.

(51) Lopez-Armada M, Carames B, Martin M, Cillero-Pastor B, Lires-Dean M, Fuentes-Boquete I, Arenas J and Blanco F. Mitochondrial activity is modulated by TNFα and IL-1β in normal human chondrocyte cells. *Osteoarthr. Cartil.* (2006) 14: 1011-22.

(52) Maneiro E, Lopez-Armada M, De Andres M, Carames B, Martin M, Bonilla A, Del Hoyo P, Galdo F, Arenas J and Blanco F. Effect of nitric oxide on mitochondrial respiratory activity of human articular chondrocytes. *Ann. Rheum. Dis.* (2005) 64: 388-95.

(53) Kim J, Xu M, Xo R, Mates A, Wilson G, Pearsall IV A and Grishko V. Mitochondrial DNA damage is involved in apoptosis caused by pro-inflammatory cytokines in human OA chondrocytes. *Osteoarthr. Cartil.* (2010) 18: 424-32.

(54) Guidarelli A, Cerioni L and Cantoni O. Inhibition of complex III promotes loss of Ca2+ dependence for mitochondrial superoxide formation and permeability transition evoked by peroxynitrite. *J. Cell Sci.* (2007) 120: 1908-14.

(55) Ding Y and Li L. Lipopolysaccharide preconditioning induces protection against lipopolysaccharide-induced neurotoxicity in organotypic midbrain slice culture. *Neurosci. Bull.* (2008) 24: 209-18.

(56) Rao J, Qiu J, Qian X, Lu L, Wang P, Wu Z, Zhai Y, Zhang F, Li G and Wang X. Lipopolysaccharide preconditioning protects hepatocytes from ischemia/reperfusion injury (IRI) through inhibiting ATF4-CHOP pathway in mice. *PloS One* (2013) 8: e65568.

(57) Zhang Q, Bian H, Guo L and Zhu H. Pharmacologic preconditioning with berberine attenuating ischemia-induced apoptosis and promoting autophagy in neuron. *Am. J. Transl. Res.* (2016) 8: 1197.

(58) Cai M, Yang Q, Li G, Sun S, Chen Y, Tian L and Dong H. Activation of cannabinoid receptor 1 is involved in protection against mitochondrial dysfunction and cerebral ischemic tolerance induced by isoflurane.
The role of mitochondrial complex I in the mechanism underlying LPS-PC neuroprotection

preconditioning. *Br. J. Anaesth.* (2017) 119: 1213-23.

(59) Dave KR, Saul I, Busto R, Ginsberg MD, Sick TJ and Pérez-Pinzón MA. Ischemic preconditioning preserves mitochondrial function after global cerebral ischemia in rat hippocampus. *J. Cereb. Blood Flow Metab.* (2001) 21: 1401-10.

(60) Zhang HX, Du GH and Zhang JT. Ischemic preconditioning preserves brain mitochondrial functions during the middle cerebral artery occlusion in rat. *Neurol. Res.* (2003) 25: 471-6.

(61) Dave KR, Saul I, Busto R, Ginsberg MD, Sick TJ and Perez-Pinzon MA. Ischemic preconditioning preserves mitochondrial function after global cerebral ischemia in rat hippocampus. *J. Cereb. Blood Flow Metab.* (2001) 21: 1401-10.

(62) Stetler RA, Leak RK, Yin W, Zhang L, Wang S, Gao Y and Chen J. Mitochondrial biogenesis contributes to ischemic neuroprotection afforded by LPS preconditioning. *J. Neurochem.* (2012) 2: 125-37.

(63) Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA and Robinson JP. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. *J. Biol. Chem.* (2003) 278: 8516-25.

(64) Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G and Ellinger-Ziegelbauer H. Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of pharmacological and safety evaluation. *Sci. Rep.* (2017) 7: 45465.

This article is available online at http://www.ijpr.ir